Prithviraj Bose, MD

Articles

Future of MF

February 16th 2024

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.

Combination Therapies for MF Management

February 9th 2024

Panel experts comment on the role of combination therapies in MF and debate if these therapies will be the new standard of care.

Future of PV: Unmet Needs

February 9th 2024

Faculty offer insights into the future of PV management as well as unmet needs.

Monitoring Patients on Myelofibrosis Treatment

February 2nd 2024

Faculty discuss the best strategies to monitor patients who are receiving treatment of MF as well as commenting on when it might be appropriate to switch therapies.

Treating Patients with Myelofibrosis and Anemia

February 2nd 2024

Expert oncologists provide insights into how they might manage patients who present with anemia and myelofibrosis in their practice.

Myelofibrosis: FDA Approved Treatment Options and Updates from ASH 2023

January 26th 2024

Overview of the current FDA approved treatment options for the management of myelofibrosis as well as reviewing recent updates from ASH 2023 on the SIMPLIFY and PERSIST trials.

Role of Transplant in Myelofibrosis

January 26th 2024

Panel experts comment on the role of transplant in patients with myelofibrosis.

MAJIC-PV: Clinical Implications in PV

January 19th 2024

Experts discuss the clinical implications of the MAJIC-PV trial.

Polycythemia Vera: Choosing the Right Treatment

January 19th 2024

Panel experts talk about when to use cytoreductive therapy and which factors influence their treatment selection as well as reviewing how patients with PV are monitored.

Polycythemia Vera: Treatment Goals and Options

January 12th 2024

Faculty discuss the treatment goals for patients diagnosed with polycythemia vera and review treatment options for managing PV.

REVEAL Study: Clinical Implications

January 12th 2024

Expert oncologists discuss the REVEAL study and provide their thoughts on these data and the impact in clinical practice.

Polycythemia Vera: Assessing Risk and Genetic Testing

January 12th 2024

Experts discuss the optimal strategy for NGS testing, which alterations to test for and how to assess for risk when diagnosing and managing patients with polycythemia vera (PV).

Diagnosing Polycythemia Vera (PV)

December 19th 2023

Experts explain how polycythemia vera is diagnosed and the typical symptoms a patient may present with.

KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis

September 26th 2023

The hematologic neoplasm systemic mastocytosis is marked by the clonal proliferation of mast cells in the skin, bone marrow, gastrointestinal tract, spleen, and/or liver, caused by an activating KIT mutation in the KIT gene.

Dr Bose on the Use of Zilurgisertib With/Without Ruxolitinib to Reduce Anemia in Myelofibrosis

June 15th 2023

Prithviraj Bose, MD, discusses key data on the use of zilurgisertib alone or in combination with ruxolitinib to reduce disease-related anemia in patients with primary or secondary myelofibrosis.

Dr Bose on Spleen and Symptom Benefit With Pacritinib in Myelofibrosis

June 6th 2023

Prithviraj Bose, MD, discusses key data on the ability of pacritinib to reduce splenomegaly and disease symptoms in patients with myelofibrosis across the cytopenic spectrum.

Unmet Needs in SM Treatment

September 27th 2021

The panel of experts in SM highlight the unmet needs in the clinical care of systemic mastocytosis.

Chronic Myelomonocytic Cell Leukemia: Clinical Considerations

September 27th 2021

The panel of experts discuss the diagnosis and assessment of chronic myelomonocytic cell leukemia.

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

September 15th 2021

Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.

Dr. Bose on Risk Factors of Essential Thrombocythemia

December 3rd 2020

Prithviraj Bose, MD, discusses risk factors associated with essential thrombocythemia.